{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T03:16:42Z","timestamp":1773285402774,"version":"3.50.1"},"reference-count":90,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes &amp; Metabolism"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1016\/j.diabet.2008.01.011","type":"journal-article","created":{"date-parts":[[2008,6,4]],"date-time":"2008-06-04T09:04:33Z","timestamp":1212570273000},"page":"207-216","source":"Crossref","is-referenced-by-count":31,"title":["Type 2 diabetes: A well-characterised but suboptimally controlled disease. Can we bridge the divide?"],"prefix":"10.1016","volume":"34","author":[{"given":"L.","family":"Monnier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Colette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.R.","family":"Owens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2008.01.011_bib1","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1001\/jama.241.19.2035","article-title":"Diabetes and cardiovascular diseases: the Framingham study","volume":"241","author":"Kannel","year":"1979","journal-title":"JAMA"},{"key":"10.1016\/j.diabet.2008.01.011_bib2","first-page":"294","article-title":"Epidemiology of macrovascular disease in diabetes","volume":"5","author":"Laakso","year":"1997","journal-title":"Diabetes Rev"},{"key":"10.1016\/j.diabet.2008.01.011_bib3","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.diabet.2008.01.011_bib4","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1055\/s-2007-985157","article-title":"Acute glucose fluctuations and chronic sustained hyperglycemia as risk factors for cardiovascular diseases in patients with type 2 diabetes","volume":"39","author":"Colette","year":"2007","journal-title":"Horm Metab Res"},{"issue":"Suppl. 2","key":"10.1016\/j.diabet.2008.01.011_bib5","doi-asserted-by":"crossref","first-page":"S150","DOI":"10.2337\/dc08-s241","article-title":"Glycemic variability. Should we and can we prevent it?","volume":"31","author":"Monnier","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2008.01.011_bib6","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2337\/diacare.24.4.617","article-title":"The national diabetes education program, changing the way diabetes is treated","volume":"24","author":"Clark","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2008.01.011_bib7","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/jama.296.4.427","article-title":"Effects of quality improvement strategies for type 2 diabetes on glycemic control. A meta-regression analysis","volume":"296","author":"Shojania","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.diabet.2008.01.011_bib8","doi-asserted-by":"crossref","unstructured":"Boegner C, Fontbonne A, Gras-Vidal MF, Mouls P, Monnier L. Evaluation of a stuctured educational program for type 2 diabetes in private practice. Diabetes Metab 2008; 34, in press.","DOI":"10.1016\/j.diabet.2008.01.003"},{"issue":"Suppl. 1","key":"10.1016\/j.diabet.2008.01.011_bib9","first-page":"S12","article-title":"Standards of medical care in diabetes-2008","volume":"31","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2008.01.011_bib10","first-page":"643","article-title":"Type 2 diabetes treatment. French recommendations for good practice","volume":"32","year":"2006","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabet.2008.01.011_bib11","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.2337\/dc06-9912","article-title":"Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the study of diabetes","volume":"29","author":"Nathan","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2008.01.011_bib12","unstructured":"International Diabetes Federation Clinical guidelines task force. Guideline for type 2 diabetes. Brussels, IDF; 2005. p. 1\u201379."},{"key":"10.1016\/j.diabet.2008.01.011_bib13","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","article-title":"The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients","volume":"26","author":"Riddle","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2008.01.011_bib14","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1056\/NEJMoa075392","article-title":"Addition of biphasic, prandial or basal insulin to oral therapy in type 2 diabetes","volume":"357","author":"Holman","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2008.01.011_bib15","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMp068294","article-title":"Finding new treatments for diabetes \u2013 how many, how fast\u2026 how good?","volume":"356","author":"Nathan","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2008.01.011_bib16","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2337\/diacare.22.3.403","article-title":"Racial and ethnic differences in glycemic control of adults with type 2 diabetes","volume":"22","author":"Harris","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2008.01.011_bib17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1262-3636(07)70087-3","article-title":"Management of French patients with type 2 diabetes mellitus in medical general practice: report of the Mediab observatory","volume":"30","author":"Monnier","year":"2004","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabet.2008.01.011_bib18","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2008.01.011_bib19","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1016\/S0002-9343(02)01276-7","article-title":"B-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities","volume":"113","author":"Le Roith","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.diabet.2008.01.011_bib20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00125-002-1009-0","article-title":"The relative contributions of insulin resistance and \u03b2-cell dysfunction to the pathophysiology of type 2 diabetes","volume":"46","author":"Khan","year":"2003","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2008.01.011_bib21","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2337\/diab.37.6.667","article-title":"Lilly lecture: the triumvirate: \u03b2-cell, muscle, liver: a collusion responsible for NIDDM","volume":"37","author":"De Fronzo","year":"1988","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2008.01.011_bib22","first-page":"177","article-title":"Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes","volume":"5","author":"De Fronzo","year":"1997","journal-title":"Diabetes Rev"},{"key":"10.1016\/j.diabet.2008.01.011_bib23","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/(SICI)1096-9136(199804)15:4<290::AID-DIA570>3.0.CO;2-M","article-title":"Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast diet study","volume":"15","author":"Levy","year":"1998","journal-title":"Diabet Med"},{"key":"10.1016\/j.diabet.2008.01.011_bib24","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1365-2362.2006.01623.x","article-title":"Insulin secretion and sensitivity as determinants of HbA1c in type 2 diabetes","volume":"36","author":"Monnier","year":"2006","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.diabet.2008.01.011_bib25","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s001250100580","article-title":"The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus","volume":"44","author":"Pratley","year":"2001","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2008.01.011_bib26","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2337\/diabetes.44.11.1249","article-title":"Overview of 6 year's therapy for type 2 diabetes: a progressive disease","volume":"44","year":"1995","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2008.01.011_bib27","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1007\/BF00400597","article-title":"Role of insulin resistance in the pathogenesis of NIDDM","volume":"38","author":"Yki-J\u00e4rvinen","year":"1995","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2008.01.011_bib28","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.2337\/diabetes.45.8.1044","article-title":"Evidence for a circadian rhythm of insulin sensitivity in patients with NIDDM caused by cyclic changes in hepatic glucose production","volume":"45","author":"Boden","year":"1996","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2008.01.011_bib29","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s00125-002-0841-6","article-title":"Quantitation of basal endogenous glucose production in type II diabetes. Importance of the volume of distribution","volume":"45","author":"Radziuk","year":"2002","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2008.01.011_bib30","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.287.3.360","article-title":"Oral antihyperglycemic therapy for type 2 diabetes","volume":"287","author":"Inzucchi","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.diabet.2008.01.011_bib31","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2008.01.011_bib32","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2008.01.011_bib33","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1055\/s-0029-1212083","article-title":"Multiple sites of insulin resistance: muscle, liver and adipose tissue","volume":"107","author":"Stumvoll","year":"1999","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.diabet.2008.01.011_bib34","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1056\/NEJM198403223101203","article-title":"The dawn phenomenon: a common occurrence in both non insulin-dependent and insulin-dependent diabetes mellitus","volume":"310","author":"Bolli","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2008.01.011_bib35","doi-asserted-by":"crossref","first-page":"E214","DOI":"10.1152\/ajpendo.1979.237.3.E214","article-title":"Glucose clamp technique: a method for quantifying insulin secretion and resistance","volume":"237","author":"De Fronzo","year":"1979","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.diabet.2008.01.011_bib36","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000177523","article-title":"Stable isotopes as tracers in clinical research","volume":"33","author":"Pacy","year":"1989","journal-title":"Ann Nutr Metab"},{"key":"10.1016\/j.diabet.2008.01.011_bib37","series-title":"Tracer Methods for In Vivo Kinetics. Theory and Applications","author":"Shipley","year":"1972"},{"key":"10.1016\/j.diabet.2008.01.011_bib38","doi-asserted-by":"crossref","first-page":"758","DOI":"10.2337\/diacare.24.4.758","article-title":"Combination therapies with insulin in type 2 diabetes","volume":"24","author":"Yki-J\u00e4rvinen","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2008.01.011_bib39","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1262-3636(07)70241-0","article-title":"Addition of rapid-acting insulin to basal insulin therapy in type 2 diabetes: indications and modalities","volume":"32","author":"Monnier","year":"2006","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabet.2008.01.011_bib40","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00125-004-1342-6","article-title":"Incretins, insulin secretion and type 2 diabetes mellitus","volume":"47","author":"Vilsb\u00f8ll","year":"2004","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2008.01.011_bib41","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2337\/diacare.29.02.06.dc05-1267","article-title":"Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1","volume":"29","author":"Riddle","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2008.01.011_bib42","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/MED.0b013e32825ea2ba","article-title":"Incretins and their role in the management of diabetes","volume":"14","author":"Frias","year":"2007","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.diabet.2008.01.011_bib43","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/MED.0b013e3280a02f65","article-title":"Dipeptidyl peptidase-4 inhibitors and the management of diabetes mellitus","volume":"14","author":"Rosenstock","year":"2007","journal-title":"Curr opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.diabet.2008.01.011_bib44","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2337\/dc06-1612","article-title":"The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes","volume":"30","author":"Monnier","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2008.01.011_bib45","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s00125-005-0132-0","article-title":"Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET Study","volume":"49","author":"Yki-J\u00e4rvinen","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2008.01.011_bib46","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/(SICI)1096-9136(199709)14:9<798::AID-DIA420>3.0.CO;2-C","article-title":"Monitoring of metabolic control in patients with non-insulin-dependent diabetes mellitus on oral hypoglycaemic agents; value of evening blood glucose determination","volume":"14","author":"Guillausseau","year":"1997","journal-title":"Diabet Med"},{"key":"10.1016\/j.diabet.2008.01.011_bib47","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1007\/BF00400996","article-title":"Occurence of low blood glucose concentrations during the afternoon in type 2 (non-insulin-dependent) diabetic patients on oral hypoglycemic agents: importance of blood glucose monitoring","volume":"34","author":"Trovati","year":"1991","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2008.01.011_bib48","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1365-2362.2004.01280.x","article-title":"Global assessment for quality and safety control in type 2 diabetic patients","volume":"34","author":"Monnier","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.diabet.2008.01.011_bib49","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.diabet.2006.11.007","article-title":"Continuous glucose monitoring in patients with type 2 diabetes: why? when? whom?","volume":"33","author":"Monnier","year":"2007","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabet.2008.01.011_bib50","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1056\/NEJM199508313330902","article-title":"Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus","volume":"333","author":"De Fronzo","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2008.01.011_bib51","first-page":"89","article-title":"Metformin: a review of its metabolic effects","volume":"6","author":"Cusi","year":"1998","journal-title":"Diabetes Rev"},{"key":"10.1016\/j.diabet.2008.01.011_bib52","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMra041001","article-title":"Thiazolidinediones","volume":"351","author":"Yki-J\u00e4rvinenn","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2008.01.011_bib53","first-page":"139","article-title":"Insulin secretagogues: old and new","volume":"7","author":"Lebovitz","year":"1999","journal-title":"Diabetes Rev"},{"key":"10.1016\/j.diabet.2008.01.011_bib54","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.2165\/00003495-200161110-00008","article-title":"A review of its therapeutic use in type 2 diabetes","volume":"61","author":"Culy","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.diabet.2008.01.011_bib55","doi-asserted-by":"crossref","first-page":"518","DOI":"10.2337\/diacare.23.4.518","article-title":"Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes","volume":"23","author":"Owens","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2008.01.011_bib56","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0140-6736(01)05842-1","article-title":"Insulins today and beyond","volume":"358","author":"Owens","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2008.01.011_bib57","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1056\/NEJMra040832","article-title":"Insulin analogs","volume":"352","author":"Hirsch","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2008.01.011_bib58","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1001\/jama.289.17.2254","article-title":"Outpatient insulin therapy in type 1 and type 2 diabetes mellitus, scientific review","volume":"289","author":"De Witt","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.diabet.2008.01.011_bib59","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1001\/jama.289.17.2265","article-title":"Using new insulin strategies in the outpatient treatment of diabetes. Clinical applications","volume":"289","author":"De Witt","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.diabet.2008.01.011_bib60","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMe068264","article-title":"Thiazolidinediones for initial treatment of type 2 diabetes","volume":"355","author":"Nathan","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2008.01.011_bib61","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1262-3636(07)70174-X","article-title":"An overview of the rationale for the pharmacological strategies in type 2 diabetes: from the evidence to new perspectives","volume":"31","author":"Monnier","year":"2005","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabet.2008.01.011_bib62","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2337\/diacare.27.6.1487","article-title":"Use and abuse of HOMA modeling","volume":"27","author":"Wallace","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2008.01.011_bib63","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2337\/diacare.25.4.737","article-title":"Morning hyperglycemic excursions. A constant failure in the metabolic control of non-insulin-using patients with type 2 diabetes","volume":"25","author":"Monnier","year":"2002","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"10.1016\/j.diabet.2008.01.011_bib64","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1365-2362.30.s2.2.x","article-title":"Is postprandial glucose a neglected cardiovascular risk factor in type 2 diabetes?","volume":"30","author":"Monnier","year":"2000","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.diabet.2008.01.011_bib65","first-page":"526","article-title":"Les cycles glyc\u00e9miques dans le diab\u00e8te de type 2\u00a0: pass\u00e9 perdu ou retour vers le futur\u00a0?","volume":"25","author":"Monnier","year":"1999","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabet.2008.01.011_bib66","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1007\/s00125-005-1885-1","article-title":"Should seven be the magic number of type 2 diabetes?","volume":"48","author":"Monnier","year":"2005","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2008.01.011_bib67","doi-asserted-by":"crossref","first-page":"2S11","DOI":"10.1016\/S1262-3636(06)70479-7","article-title":"Contribution of postprandial glucose to chronic hyperglycaemia: from the \u201cglucose triad\u201d to the trilogy of \u201csevens\u201d","volume":"32","author":"Monnier","year":"2006","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabet.2008.01.011_bib68","doi-asserted-by":"crossref","first-page":"750","DOI":"10.2337\/diacare.25.4.750","article-title":"Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus (position statement)","volume":"25","author":"Sacks","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2008.01.011_bib69","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00125-005-0073-7","article-title":"How should HbA1c measurements be reported?","volume":"49","author":"Gorus","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2008.01.011_bib70","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.2337\/dc07-9925","article-title":"Consensus statement on the worldwide standardization of the hemoglobin A1c measurement","volume":"30","author":"Consensus Committee","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2008.01.011_bib71","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00125-006-0141-7","article-title":"Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review","volume":"49","author":"Natali","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2008.01.011_bib72","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2337\/diacare.26.3.881","article-title":"Contributions of fasting and postprandial plasma increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c","volume":"26","author":"Monnier","year":"2003","journal-title":"Diabetes Care"},{"issue":"Suppl. 1","key":"10.1016\/j.diabet.2008.01.011_bib73","doi-asserted-by":"crossref","first-page":"42","DOI":"10.4158\/EP.12.S1.42","article-title":"Contributions of fasting and postprandial glucose to hemoglobin A1c","volume":"12","author":"Monnier","year":"2006","journal-title":"Endocr Pract"},{"key":"10.1016\/j.diabet.2008.01.011_bib74","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/jcem-63-2-492","article-title":"Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses","volume":"63","author":"Nauck","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2008.01.011_bib75","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/01.med.0000151395.52819.47","article-title":"Glucagon-like peptide 1: physiology and therapeutic potential","volume":"12","author":"Holst","year":"2005","journal-title":"Curr Opin Endocrinol Diabetes"},{"key":"10.1016\/j.diabet.2008.01.011_bib76","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/01.med.0000155379.11926.e2","article-title":"Glucagon-like peptide 1 agonists and dipeptidyl peptidase IV inhibitors: new therapeutic agents for the treatment of type 2 diabetes","volume":"12","author":"Sinclair","year":"2005","journal-title":"Curr Opin Endocrinol Diabetes"},{"key":"10.1016\/j.diabet.2008.01.011_bib77","doi-asserted-by":"crossref","first-page":"421","DOI":"10.5414\/CPP41421","article-title":"Review of acarbose therapeutic strategies in the long-term treatment and in the prevention of type 2 diabetes","volume":"41","author":"Breuer","year":"2003","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.diabet.2008.01.011_bib78","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1111\/j.1742-1241.2006.01187.x","article-title":"Pramlintide in the treatment of diabetes","volume":"60","author":"Edelman","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.diabet.2008.01.011_bib79","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/ncpendmet0454","article-title":"Is pramlintide a safe and effective adjunct therapy for patients with type 1 diabetes?","volume":"3","author":"Monnier","year":"2007","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.1016\/j.diabet.2008.01.011_bib80","doi-asserted-by":"crossref","first-page":"580","DOI":"10.2337\/diacare.19.6.580","article-title":"Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I (7\u201336) amide in type 1 diabetes","volume":"19","author":"Creutzfeldt","year":"1996","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2008.01.011_bib81","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1262-3636(07)70097-6","article-title":"Self-monitoring of blood glucose in diabetic patients: from the least common denominator to the greatest common multiple","volume":"30","author":"Monnier","year":"2004","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabet.2008.01.011_bib82","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1001\/jama.295.14.1688","article-title":"Assessing glycemia in diabetes using self-monitoring blood glucose and HbA1c","volume":"295","author":"Saudek","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.diabet.2008.01.011_bib83","first-page":"467","article-title":"Autosurveillance glyc\u00e9mique dans le diab\u00e8te de type 1 et de type 2","volume":"19","author":"Monnier","year":"2007","journal-title":"Sang Thromb Vaiss"},{"key":"10.1016\/j.diabet.2008.01.011_bib84","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJM199209033271007","article-title":"Carbohydrate metabolism in non-insulin-dependent diabetes mellitus","volume":"327","author":"Dinneen","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2008.01.011_bib85","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1093\/ajcn\/83.6.1306","article-title":"Food glycemic index, as given in glycemic index tables, is a significant determinant of glycemic responses elicited by composite breakfast meals","volume":"83","author":"Wolever","year":"2006","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.diabet.2008.01.011_bib86","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.2337\/diacare.17.11.1300","article-title":"Comparison of pharmacokinetics and pharmacodynamics of short and long-term glyburide therapy in NIDDM","volume":"11","author":"Jaber","year":"1994","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2008.01.011_bib87","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1055\/s-2007-979833","article-title":"Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients","volume":"28","author":"Rosenkranz","year":"1996","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.diabet.2008.01.011_bib88","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.2337\/diabetes.49.12.2142","article-title":"Pharmaco-kinetics and pharmacodynamics of subcutaneaous injection of long-acting human insulin analog glargine, NPH insulin and ultralente human insulin and continuous subcutaneous infusion of insulin lispro","volume":"49","author":"Lepore","year":"2000","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2008.01.011_bib89","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2337\/diacare.23.6.813","article-title":"Pharmacokinetics of [125]I-labelled insulin glargine (HOE 901) in healthy men","volume":"23","author":"Owens","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2008.01.011_bib90","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.2337\/diabetes.53.6.1614","article-title":"Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes","volume":"53","author":"Heise","year":"2004","journal-title":"Diabetes"}],"container-title":["Diabetes &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363608000621?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363608000621?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,11]],"date-time":"2019-05-11T21:53:58Z","timestamp":1557611638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363608000621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":90,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["S1262363608000621"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2008.01.011","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}